newsfilter
← Latest News
GlobeNewswire·

Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives

IMRN
  • Immuron Limited (ASX: IMC; NASDAQ: IMRN) engaged LifeSci Capital as exclusive financial advisor to evaluate strategic initiatives aimed at maximizing shareholder value.
  • Potential strategic initiatives under consideration include mergers, acquisitions, licensing, or other transactions, with no assurance of any specific outcome.
  • The company will not provide updates unless the Board approves a specific transaction or disclosure is deemed appropriate.
  • Immuron is an Australian biopharmaceutical company developing orally delivered targeted polyclonal antibodies for infectious diseases using engineered hyper-immune bovine colostrum.
  • Travelan® (IMM-124E) is an orally administered passive immunotherapy that binds to diarrhea-causing bacteria to prevent travelers' diarrhea, marketed as a listed medicine in Australia, a natural health product in Canada, and a dietary supplement in the U.S.
  • IMM-124E utilizes antibodies from ETEC-vaccinated cows to target LPS, CFA-I, and Flagellin antigens across 13 ETEC serotypes.
  • Immuron is developing IMM-529 as an adjunctive therapy for recurrent Clostridioides difficile infection (CDI) in collaboration with Monash University, targeting Toxin B, spores, and surface layer proteins.
  • Pre-clinical data for IMM-529 shows potential for preventing primary disease (80%), protecting against recurrence (67%), and treating primary disease (78.6%).
  • Immuron holds an exclusive distribution agreement with Calmino group AB for ProIBS® in Australia and New Zealand, a medical device containing Aloe barbadensis Mill. (AVH200®) for IBS symptoms.
  • Usability studies for ProIBS® indicate 94% of users found it helpful, 91% experienced daily life improvement, and 98% would recommend it.
  • The Australian IBS treatment market was valued at approximately AU$221.14 million in 2025 with a projected annual growth rate of 3.28%.
Company
Immuron Limited
Keywords
Nasdaq:IMRN, Immuron Limited, Immuron, Immuron Limited, IMRN, IMC